Article Text

PDF
DI-082 Improvement in the lipid profile of hiv-infected patients after switching to Rilpivirine/Emtricitabine/Tenofovir
  1. S Ortonobes Roig1,
  2. M De Antonio Cuscó1,
  3. N Carballo Martínez1,
  4. E Gonzalez Colominas1,
  5. R García Paricio1,
  6. H Knobel2,
  7. S Luque1
  1. 1Hospital Del Mar Parc de Salut Mar, Pharmacy Department, Barcelona, Spain
  2. 2Hospital Del Mar Parc de Salut Mar, Infection Disease Department, Barcelona, Spain

Abstract

Background Dyslipidaemia has been associated with antiretroviral therapy (ART). Rilpivirine, a new second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), has a more favourable lipid profile.

Purpose To study the changes in the lipid profile of HIV-infected patients after switching from any ART to rilpivirine/emtricitabine/tenofovir and to assess the efficacy of the switch.

Material and methods Observational study including all patients switching to rilpivirine/emtricitabine/tenofovir from April 2013–2014 in our cohort of 1550 HIV-infected patients. Data: demographics, previous ART, CD4+count, HIV viral load and lipid parameters at baseline and six months after the switch. All patients were classified as normal baseline or altered lipid profile (NLP or ALP) according to National Cholesterol Education Program cut-offs. Differences between baseline and final values of the lipid parameters were compared between the two groups. Quantitative data were expressed as median (Q1/Q3).

Results 131 patients switched to rilpivirine/emtricitabine/tenofovir: 109 (83.2%) male; age: 43.7 (37.6/50.2) years. Previous ART included 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus: protease inhibitor 46 (35.1%) patients, NNRTI 82 (62.6%) and integrase inhibitor 3 (2.3%). Baseline vs. final: CD4+count 619 (437/811) vs. 653 (489/830) cell/mcL (p = 0.067) and%patients with HIV-RNA <50 copies/mL: 84.5% vs. 85.7% (p = 0.788).

Abstract DI-082 Table 1

Conclusion

  • Rilpivirine/emtricitabine/tenofovir improved the lipid profile of HIV-infected patients, while maintaining the immunological and virological efficacy of the ART

  • The reduction in the lipid parameters was significantly higher in patients with altered lipid profile at baseline.

References and/or acknowledgements No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.